Melanoma is widely known as the most lethal skin cancer. Specific tumor-related mortality can be significantly reduced if diagnosis and treatment are properly performed during initial phases of the disease. The current search for biomarkers in early-stage melanomas is a high-priority challenge for physicians and researchers. We aimed to assess the immunoexpression of BRAFV600E and KIT in a case series consisting of 44 early-stage melanomas. Formalin-fixed paraffin-embedded samples were systematically evaluated using a semi-quantitative method based on scores of percentage and intensity for immunostained tumor cells. We observed significant concordance between BRAFV600E and KIT immunoexpression in thin invasive melanomas. Our findings corroborate previous evidence showing abnormal expression of proteins associated with MAPK intracellular signaling pathway in early-stage melanomas.
INTRODUCTION
Cutaneous The tumor may arise de novo or from preexisting or atypical nevi. 4 It is usually related to intermittent sun exposure and/or family history. 4 Early-stage melanomas can be divided into melanoma in situ (MIS) and thin invasive melanoma (TM). MIS is the first stage of histologically detectable malignant melanocytic lesion and is characterized by lentiginous proliferation of atypical melanocytes. 5 TM is defined as invasive disease with thickness less than 1.0 millimeter. 6 Biologically, CM is a complex disease influenced by genetic and environmental factors. Stepwise acquisition of mutations leads to activation of oncogenes and inactivation of tumor suppressor genes. 4 Constitutive activation of the mitogen-activated protein kinase (MAPK) pathway represents a crucial pathogenic mechanism in several types of cancer. 7 Murine sarcoma viral oncogene homolog B (BRAF) gene plays a major role in the regulation of MAPK pathway.
Activating BRAF mutations occur in 40-50% of CM. 8 BRAF V600E is the most common mutation and represents about 90% of BRAF mutations. 8 KIT proto-oncogene (KIT) encodes a homonymous tyrosine--kinase known to activate several signaling pathways, including the MAPK and phosphoinositide-3 kinase (PI3K) pathways. It has been suggested that KIT plays a role in the early pathogenesis of CM. 9 We assessed the immunoexpression of BRAF V600E and KIT in a case series of early-stage skin melanomas and discussed our results in light of the current literature.
MATERIAL AND METHODS
This retrospective study was based on formalin-fixed paraffin-embedded samples obtained from the archives of a private dermatopathology laboratory in São Paulo, Brazil. Inclusion criteria:
(1) early-stage melanoma diagnosis (MIS or TM); (2) paraffin block available; and (3) sufficient amount of tumor tissue.
Immunohistochemical assays were performed in 3-micrometer-thick whole tissue sections. Immunolabelling was scored based on percentage: absent (0), 1-10% (1), 11-50% (2), and greater than 50% (3); and intensity: absent (0), weak (1), moderate (2) and strong (3). Final score was obtained from the sum of both parameters. A positive score was defined as greater than or equal to 3. All slides were reviewed and interpreted by pathologists. immunoexpression in the TM subgroup.
DISCUSSION
In recent decades, public awareness of sun damage and its harmful cumulative effects on the human skin has contributed to a significant increase in earlier detection of CM. Early-stage disease is potentially curable with local surgical resection, while thick tumors are much more likely to behave aggressively.³ Efficient markers with major prognostic significance remain to be defined.
Several intracellular signaling pathways have been implicated in melanoma genesis and progression. 4 The present study is not free of limitations. We consider the lack of molecular genomic assessment, the small sample size, and the retrospective approach without follow-up data as the most relevant ones. The high cost of molecular methods and insufficient amount of available tumor tissue were major hurdles for us. Nevertheless, our results obtained from a previously unpublished case series consisting exclusively of early-stage tumors help further characterize and elucidate melanoma emergence and progression in the Brazilian population.
Briefly, we described the frequency of BRAF V600E and KIT immunoexpression in an early-stage melanoma series and observed significant concordance between BRAF V600E and KIT labeling in the TM subgroup. Our findings corroborate previous evidence showing abnormal expression of proteins associated with MAPK intracellular signaling pathway in early tumors.q
